In the SURMOUNT-1 trial published in the New England Journal of Medicine, participants taking Zepbound achieved remarkable average weight reductions: 15% (34 lbs) at the 5mg dose, 19.5% (43 lbs) at 10mg, and 20.9% (approximately 48 lbs) at the highest 15mg dose over 72 weeks
Jastreboff, MD, PhD Director, Weight Management & Obesity Prevention Yale School of Medicine, New Haven, Connecticut Professor Ania Jastreboff has been a principal investigator for pivotal GLP3 clinical trials, including the landmark phase 2 obesity study published in the New England Journal of Medicine
The GLP-1/GIP receptor agonist also showed promising benefit in pre-diabetic patients
Microdosing GLP-1 medication is not FDA-approved and is used as an off-label practice, which is not supported by any clinical trials
The study said high gas prices, rising GLP-1 usage and cuts in the number of people receiving government food aid are all affecting grocery spending
41,42 GLP-1R is expressed in the cardiovascular system, and its knockout has implications for cardiovascular function